ReviewCancer management and research2026
Research Progress of HER2 in Cervical Carcinoma.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) remains a major gynecological malignancy worldwide, and patients with recurrent, metastatic, or treatment-resistant disease continue to have limited therapeutic options. Human epidermal growth factor receptor 2 (HER2) is a proto-oncogenic receptor tyrosine kinase involved in tumorigenesis and progression through gene amplification, activating mutation, and protein overexpression. Although HER2 has been extensively studied and successfully targeted in breast and gastric cancers, its biological and therapeutic significance in CC remains less clearly defined and appears to vary according to histological subtype and molecular context. Current evidence suggests that HER2 alterations are relatively uncommon in unselected CC populations but may be enriched in selected adenocarcinoma subgroups, including gastric-type and other human papillomavirus (HPV)-independent variants. This review synthesizes current evidence regarding the structure, function, expression patterns, prognostic implications, testing criteria, and therapeutic relevance of HER2 in CC. Particular attention is given to HER2-directed antibody-drug conjugates, especially trastuzumab deruxtecan (T-DXd), which have emerged as an important recent therapeutic advance and have renewed interest in HER2 as an actionable target in selected patients with HER2-expressing cervical carcinoma. This review further highlights the need for biomarker-driven patient selection, standardized HER2 assessment, and rational integration of HER2-directed strategies into precision treatment for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.